Recent News

• 07.30.2026 - HUTCHMED Reports 2026 Interim Results
• 07.02.2026 - HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
• 06.30.2026 - HUTCHMED to Announce 2026 Half-Year Financial Results
• 06.25.2026 - HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
• 06.12.2026 - HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
• 05.22.2026 - HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
• 05.21.2026 - HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
• 04.29.2026 - HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
• 04.09.2026 - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
• 03.23.2026 - HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

Recent Filings

• 07.30.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.30.2026 - EX-99.1 EX-99.1
• 07.02.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.02.2026 - EX-99.1 EX-99.1
• 06.30.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.30.2026 - EX-99.1 EX-99.1
• 06.29.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.29.2026 - EX-99.1 EX-99.1
• 06.25.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.25.2026 - EX-99.1 EX-99.1